Font size
WorksheetsPAXUS PM Refreshing Quiz
Total questions: 10
Worksheet time: 10mins
PAXUS PM is well known as novel nanotechnology non cremophor paclitaxel formulation, and PM stands for
Product Material from biological component of human albumin
Polimeric Micelle from non biologic and biodegradable stuff
Proof material from high temperature and humidity
Protective matter from high acidity and unstable temperature
Choose the correct technology to produce paclitaxel of PAXUS PM
Semi synthesis
Extraction
Fully synthesis
Plant Cell Culture
Below is the right statement about the feature of PAXUS PM, except ....
Non cremophor formulation of paclitaxel
Has similar results like conventional paclitaxel
Has phase III clinical study in Metastatic Breast Cancer with Asian population
Studied in locally advanced pancreatic cancer both as single and combination regimen
Please choose the group of indications for PAXUS PM below
MBC. NPC, APC
NSCLC, Cervical Ca, MBC
MBC, NSCLC, Ovary Ca
MBC only as single drug
Below are the correct statements about bioequivalent study between Paxus PM and nab-paclitaxel, except
Done in multi centers & multi countries with more than 100 cases
Has more higher Maximum Tolerated Dose (MTD) vs Nab-paclitaxel
MBC with 260 mg/m2 dosing given in 30 minutes of infusion rate
NSCLC with 260 mg/m2 given in 30 minutes of infusion rate
The recommended dose of PAXUS PM as single agent in metastatic breast cancer according to phase III study is ...
175 mg/m2
200 mg/m2
260 mg/m2
300 mg/m2
Below are solid tumors that can be treated with PAXUS PM beside the on-label indication named before ....
Head & Neck Ca, Prostate Ca
Gastric Ca, Cervical Ca
Thymic Ca, Biliary Ca
Sarcoma, Glioma
Below are the common adverse events of PAXUS PM
Headache, Rashes, Anemia
Alopecia, Diarrhea, Neutropenia
Allergic reactions, thrombocytopenia, rashes
Alopecia, neutropenia, neuropathy
Below are the results of published phase III clinical studies in MBC, except ....
Manageable both non-hematology and hematological toxicities
Improved CR and PFS vs cremophor-based and Nab-Paclitaxel
Prolonged median OS more than 5 months vs cremophor - based formulation & Nab-Paclitaxel (28.6 months vs 12.7 month vs 15.2 months)
Higher dose than nab-paclitaxel with similar infusion rate of administration
Which statement is correct about PAXUS PM?
PAXUS PM has no pre-clinical trials, only clinical stages
PAXUS PM only conducted phase I clinical studies and limited pre-clinical evidences in solid tumors
No phase II and III clinical studies were published last 10 year ago
Has complete owned pre-clinical, phase I, II, III, IV and BE vs nab-paclitaxel
